10-Q quarterly report · filed Nov 2, 2026

CERUS CORP (CERS) Q3 2026 10-Q Quarterly Report

Short answer

CERUS CORP (CERS) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $58M with net income of −$550,000.

Q3 2026 key financials · XBRL

Revenue
$58M
+0.5% QoQ
Net income
−$550,000
−2794.7% YoY · +81.3% QoQ
Operating margin
0.7%
EPS (diluted)
−$0.01
+0.0% QoQ

Source: XBRL data from the CERUS CORP (CERS) Q3 2026 10-Q on SEC EDGAR. USD.

CERUS CORP Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $64.018M, up $3.781M YoY, driven by platelet kits, IFC sales and EMEA LED illuminators
  • Product gross margin 52% vs 53% YoY, pressured by foreign exchange, inventory costs and tariffs
  • Product revenue $57.714M, up $5.016M, while government contract revenue fell $1.235M to $6.304M
  • Cash, investments and restricted cash $57.734M vs $83.518M at December 31, 2025
  • Near-term headwinds: tariffs, conflicts, supply-chain disruption and potential reductions or delays in BARDA funding

Risk Factors

  • New regulatory risk: EU EUDAMED modules become mandatory May 28, 2026, increasing compliance costs
  • BARDA funding risk: 2016 Agreement options discontinued, while 2024 Agreement potential funding increased to $209.0 million
  • Regulatory approval risk: ANSM review continues for the red blood cell system’s MDR application after prior closure
  • Market risk: U.S. platelet shortages may reduce demand for INTERCEPT-treated products despite safety-compliance options
  • Customer concentration risk: American Red Cross represents the largest single portion of U.S. blood collection market

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other CERUS CORP quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.